Association of erlotinib and acitretin for the treatment of Olmsted syndrome with erythromelalgia in a pediatric patient

Read full text Summarise with VIRAT
Authors: Luna Azulay‐Abulafia, Joice Rodrigues Fagundes, Edgar Ollague Cordova, Karla Diniz Pacheco, Alain Hovnanian
Cited by: 0
References: 6

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Association of erlotinib and acitretin for the treatment of Olmsted syndrome with erythromelalgia in a pediatric patient ଝ Dear Editor, Olmsted Syndrome (OS) is a rare genodermatosis characterized by painful and mutilating Palmoplantar Keratoderma (PPK) and periorificial keratotic plaques.It is an orphan disease, which represents a therapeutic challenge.OS is most often caused by dominant gain-of-function pathogenic variants in the TRPV3 gene.We report an 8-year-old male suffering from OS with erythromelalgia, who was treated since the age of 18-months with acitretin and topicals, leading to only minor improvement.At the age of 5-years, oral erlotinib was added to acitretin, resulting in a significant improvement in pain, keratoderma and erythromelalgia, with sustained efficacy and safety.The patient is a full-term male newborn from nonconsanguineous parents with no family history of skin disease.From the age of 5-months, the patient developed painful and pruritic PPK.Over time, PPK progressed bilaterally and was associated with periorificial hyperkeratosis.Upon physical examination, the patient presented with asymmetric, thick, and localized or diffuse bilateral PPK (Fig. 1A), keratotic plaques around the anus, ears, and mouth alongside leukokeratosis on the tongue (Fig. 1B).The scalp hair was fine and reduced.Congenital left-sided clubfoot was additionally observed.Genomic DNA was extracted from the patient's peripheral blood for genetic testing.Next-generation sequencing analysis using a custom gene panel revealed a heterozygous c.1703>T; p.GIy568VaI pathogenic missense variant in the TRPV3 gene.The parents did not carry this variant.Topical treatments (0.1% retinoic acid cream, 20% urea cream, corticosteroids and emollients) were ineffective.Acitretin treatment (1 mg/kg/day) was started at 18-

Fields of Study & Subjects

Genetic and rare skin diseases. Dermatology and Skin Diseases Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Anais Brasileiros de Dermatologia
Volume
101
Issue
2
Pages
501313–501313
Publication date
1 March 2026
Language
EN